Rakovina Therapeutics Stock Today
| RKV Stock | CAD 0.12 0.01 9.09% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Rakovina Therapeutics is selling for under 0.12 as of the 21st of March 2025; that is 9.09 percent increase since the beginning of the trading day. The stock's lowest day price was 0.1. Rakovina Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Certain Worldwide Rights of NewGen Therapeutics, Inc. comprises PARP inhibitor program technology. RAKOVINA THERAPEUTICS is traded on Commodity Exchange in Exotistan. The company has 90.29 M outstanding shares of which 37.91 K shares are at this time shorted by private and institutional investors with about 0.14 days to cover all short positions. More on Rakovina Therapeutics
Moving together with Rakovina Stock
Moving against Rakovina Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rakovina Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Rakovina Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Rakovina Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Mads Daugaard | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Rakovina Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Rakovina Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsRakovina Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rakovina Therapeutics' financial leverage. It provides some insight into what part of Rakovina Therapeutics' total assets is financed by creditors.
| |||||
Rakovina Therapeutics (RKV) is traded on TSX Venture Exchange in Canada and employs 4 people. Rakovina Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Rakovina Therapeutics's market, we take the total number of its shares issued and multiply it by Rakovina Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Rakovina Therapeutics classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 90.29 M outstanding shares of which 37.91 K shares are at this time shorted by private and institutional investors with about 0.14 days to cover all short positions.
Rakovina Therapeutics has accumulated about 4.37 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Check Rakovina Therapeutics Probability Of Bankruptcy
Ownership AllocationRakovina Therapeutics owns a total of 90.29 Million outstanding shares. Rakovina Therapeutics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rakovina Ownership Details
Rakovina Therapeutics Risk Profiles
Although Rakovina Therapeutics' alpha and beta are two of the key measurements used to evaluate Rakovina Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.82 | |||
| Standard Deviation | 8.27 | |||
| Variance | 68.43 | |||
| Risk Adjusted Performance | 0.0061 |
Rakovina Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Rakovina Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Rakovina Therapeutics Corporate Executives
Elected by the shareholders, the Rakovina Therapeutics' board of directors comprises two types of representatives: Rakovina Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rakovina. The board's role is to monitor Rakovina Therapeutics' management team and ensure that shareholders' interests are well served. Rakovina Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rakovina Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.